Q4 RESULTS: Myriad stumbles as celebrity sheen fades
This article was originally published in Clinica
Executive Summary
Myriad Genetics beat analyst expectations in its fourth quarter but its guidance disappointed Goldman Sachs’ Isaac Ro. Nonetheless, the molecular diagnostic firm’s share price rose 2% to close at $39.00 on 12 August, the day it reported the results.